SUMMARYBackground: Endoscopic therapies and continuous intravenous omeprazole can decrease the morbidity and duration of hospital stay of patients with high-risk peptic ulcer. Aim: To evaluate the role of oral omeprazole in highrisk bleeders. Methods: After injection therapy of 160 patients with high-risk peptic ulcer, 80 received oral omeprazole and 80 received placebo, and all were followed up. Results: One hundred and forty-nine patients (71 omeprazole and 78 placebo) completed the study. Eleven patients were excluded from the study. Thirtyseven (25%) patients had gastric ulcer and 112 (75%)

The aim of this study was to evaluate the effects of Nigella sativa (N. sativa) in addition to quadruple‐therapy on Helicobacter pylori eradication, dyspepsia, biochemical‐markers, and quality of life in infected patients. In this double‐blind placebo‐controlled clinical‐trial, 51 H. pylori infected patients with functional dyspepsia were randomly assigned to treatment (quadruple‐therapy with 2 g/day N. sativa) or placebo groups (quadruple‐therapy with 2 g/day placebo) for 8 weeks. Serum levels of interleukin‐8 (IL‐8), high‐sensitivity C‐reactive protein (hs‐CRP) and malondialdehyde, quality of life, dyspepsia, food‐intake, body‐weight, and body mass index (BMI) were evaluated at the baseline and at the end of the study. H. pylori eradication was evaluated at the end of the intervention. At the end of the study, H. pylori eradication was more in the N. sativa group compared with the placebo (p = .01). Weight, BMI, and dietary‐intake (p < .05) increased significantly as compared with placebo. A significant improvement was also observed in patients' quality of life in the treatment group compared with the placebo (p < .05). The differences of biochemical‐markers and dyspepsia between the two groups were not significant. So, N. sativa supplementation with medical treatment may have beneficial effects on H. pylori eradication, weight, BMI, dietary‐intake, and quality of life in infected patients.

The Persian version of the CLDQ, a disease-specific questionnaire for measuring health-related quality of life, is accepted by liver transplantation candidates with adequate reliability and validity. There is no significant correlation of Child Pugh classification and MELD score with quality of life.

Objective This double-blind, placebo-controlled, clinical trial was conducted to define the effects of Nigella sativa (N. Sativa) powder plus conventional medical treatment of Helicobacter pylori (H. pylori) on serum ghrelin level and appetite in H. pylori-infected patients. Methods In the present study, 51 H. pylori-positive patients were randomly allocated to treatment (n = 26) or placebo (n = 25) groups. They received 2 g/day N. Sativa with quadruple therapy or 2 g/day placebo plus quadruple therapy for 8 weeks. The serum level of ghrelin was assessed before and after the intervention. Appetite was evaluated at the onset and at the end of the intervention. Results At the end of the study, the appetite of the treatment group improved significantly compared with the placebo group (P = 0.02). Statistically, the difference in serum ghrelin levels between the study’s groups was insignificant (P > 0.05). Conclusion Supplementation with N. Sativa powder may be a beneficial adjunctive therapy in H. pylori-infected patients. Trial registration This study was registered in the Iranian Registry of Clinical Trials (IRCT20170916036204N7) on 08/08/2018.